802535-83-7Relevant academic research and scientific papers
Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors
Caldarelli, Marina,Angiolini, Mauro,Disingrini, Teresa,Donati, Daniele,Guanci, Marco,Nuvoloni, Stefano,Posteri, Helena,Quartieri, Francesca,Silvagni, Marco,Colombo, Riccardo
supporting information; experimental part, p. 4507 - 4511 (2011/09/12)
The synthesis and SAR of a series of novel pyrazolo-quinazolines as potent and selective MPS1 inhibitors are reported. We describe the optimization of the initial hit, identified by screening the internal library collection, into an orally available, potent and selective MPS1 inhibitor.
Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl] amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor
Brasca, Maria Gabriella,Amboldi, Nadia,Ballinari, Dario,Cameron, Alexander,Casale, Elena,Cervi, Giovanni,Colombo, Maristella,Colotta, Francesco,Croci, Valter,D'Alessio, Roberto,Fiorentini, Francesco,Isacchi, Antonella,Mercurio, Ciro,Moretti, Walter,Panzeri, Achille,Pastori, Wilma,Pevarello, Paolo,Quartieri, Francesca,Roletto, Fulvia,Traquandi, Gabriella,Vianello, Paola,Vulpetti, Anna,Ciomei, Marina
experimental part, p. 5152 - 5163 (2010/03/04)
The discovery of a novel class of inhibitors of cyclin dependent kinases (CDKs) is described. Starting from compound 1, showing good potency as inhibitor of CDKs but being poorly selective against a panel of serine-threonine and tyrosine kinases, new analogues were synthesized. Enhancement in selectivity, antiproliferative activity against A2780 human ovarian carcinoma cells, and optimization of the physical properties and pharmacokinetic profile led to the identification of highly potent and orally available compounds. Compound 28 (PHA-848125), which in the preclinical xenograft A2780 human ovarian carcinoma model showed good efficacy and was well tolerated upon repeated daily treatments, was identified as a drug candidate for further development. Compound 28 is currently undergoing phase I and phase II clinical trials.
PYRAZOLO-QUINAZOLINE DERIVATIVES,PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
-
Page 155-156, (2008/06/13)
Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
